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locations (G1: 79,27% single and 20,73% multiple, G2: 75% 
and 25%).
For SA, taking into account the clinical improvement and 
complete healing, interesting results were highlighted compar-
ing T1 vs T2 (29,4% vs 56,81%, 23,5% vs 31,81%), T1+T2 vs 
T3+T4+T5 (49,18% vs 87,82%, 29,50% vs 81,74%) and T3 
vs T4+T5 (50% vs 92,23%, 50% vs 85,44%).
Results comparing an early approach (stage I) vs therapies 
in stage II and III lled almost twice as much to stage 0 (80% 
vs 57,14%)
CONCLUSIONS: In SB no differences between non surgical 
and surgical approach were highlighted.
In both groups the use of laser significantly improves the out-
come of treatments.
Surgical laser approach in Stage III led to complete healing 
in all cases.
Early surgical approach leads in almost every cases to a com-
plete healing.
Further studies are needed to test if the suspension of the 
administration of drugs could lead to higher percentage 
of improvement and/or healing in patients treated through 
Zoledronic acid combined with antiresorptive-antiangiogenic 
drugs or antiresorptive-antiangiogenic drugs only.
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BACKGROUND: The oral cavity is an anatomical structure 
characterized by the juxtaposition of soft and hard tissues, 
and is continuously threatened by the external environment 
and foreign materials. Diseases and disorders caused by oral 
microorganisms are very common, particularly dental car-
ies, periodontitis and halitosis. Oral diseases can also arise 
in the setting of a systemic compromission due to immuno-
deficiency, whose clinical importance is becoming more and 
more outstanding. In such conditions, oral manifestations may 
be more frequent, or even more severe. The aim of this study 
is to highlight oral and more specifically orthodontic mani-
festations shared by individuals with immunodeficiencies, 
so that precautions that will improve patients’ quality of life, 
especially in regard to dental aspects, may be established in 
the future.
METHODS: A group of subjects (11 males and 9 females, 
mean age 12-20 years) was selected from patients with immu-
nodeficiencies who referred to the Immunohaematology 
Department of San Raffaele Scientific Institute in Milan, 
Italy, between 2010 and 2015. All these subjects underwent 
the following iter: laboratory tests, microbiological, haema-
tological and immunological evaluation, brain MRI, brain 
CT, orthopantomography and oral examination, hand–wrist 
radiography BACKGROUND:ed at evaluating the effects of 
pathologies of the immune system on patients’ growth.
RESULTS: Medical signs and symptoms which are charac-
teristic of peculiar immunodeficiency syndromes, such as 
recurrent infections, eczema, thrombocytopenia, anaemia, 
petechiae, ecchymosis, mucosal bleeding and major bleed-
ing, were usually observed. The oral examination revealed 
gingivitis, periodontitis, aphthous lesions, gingival bleeding, 
petechiae in the oral mucosa, severe oral infections (caries, 
pulpitis, abscesses). As for orthodontic aspects, we found 
a higher incidence of alterations in the physiological erup-
tive sequence, i.e. inclusions and transpositions, probably 
caused by untreated inflammatory and infectious processes. 
Infections affecting permanent teeth may also result in mal-
occlusion, which possibly paves the way for future skeletal 
problems. In addition to that, immunodeficiency may compro-
mise orthodontic treatments and interfere with their purpose 
of aligning teeth and solving skeletal issues.
CONCLUSIONS: Since immunodeficiencies comprise a wide 
spectrum of symptoms and complications, it is mandatory to 
increase awareness of this entity. Although little attention was 
dedicated to this matter in the literature, a multidisciplinary 
approach for the treatment of these patients should always 
include the dentist, whose role is to intercept pathologies of 
the oral cavity and ultimately improve their quality of life.
Early onset ONJ in patient treated with deno-
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BACKGROUND:
Osteonecrosis of the jaw (ONJ) is a no longer serious com-
plication related to many drugs, notoriously aminobisphos-
phonate (BP) but also antiresorptives and anti-angiogenetics. 
Several cases of denosumab-related ONJ have been reported 
and the overall incidence is similar to that for BP-related ONJ. 
It is known that, concomitant administration of two or more of 
these drugs increase considerably the risk of onset and sever-
ity of ONJ.
We describe a case report of early onset ONJ in oncologic 
patient treated with denosumab and bevacizumab, with nega-
tive anamnesis for BP administration.
METHODS: In March 2015, a 58-year-old female patient 
was referred to our department for pain and swelling of upper 
left maxilla.
Patient reported the following anamnestic data: in 2010, for 
the diagnosis of breast cancer, she was underwent to right 
quadrantectomy surgery and radiant treatment; she was treated 
with monthly subcutaneous injections of 120 mg denosumab 
(eight doses from April 2014 to November 2014) and bevaci-
zumab (five doses from August 2014 to November 2014); she 
had no history head and neck radiotherapy and BP administra-
tion. One trigger (local risk factor for ONJ) has been recog-
nized: extractions of maxillary left second premolar and first 
molar have been performed few months before.
Intraoral examination showed a painful area of bone exposure 
in the left posterior maxilla and erythematous soft tissue with 
purulent discharge and swelling was detected.
After OPT and CBCT scans, bone necrosis was classified as 
stage II, according to Bedogni et al.
Systemic antibiotic (ampicillina/sulbactam intramuscularly 
twice daily for 8 days and metronidazole (off-label use) 250 
mg orally twice daily for 8 days), local antiseptics (chlo-
rhexidine 0.2% mouth rinses and 0.5% chlorhexidine gel) 
were administered. The patient was referred to Oral and 
Maxillofacial surgery for surgical management.
CONCLUSIONS: It is widely described in literature that 
early-onset ONJ is more hazardous in oncologic patients, 
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particularly when taking BP plus another ONJ-related drug. 
It is our opinion that it is necessary to give attention for pre-
vention protocols also to the patients in therapy with all drugs 
related to ONJ. 
Overexpression of Nicotinamide n-Methyl-
transferase in HSC-2 OSCC cell line: effect on 
apoptosis and cell proliferation.
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BACKGROUND: The oral squamous cell carcinoma (OSCC) 
is the most common head and neck malignancy, representing 
up to 90% of oral cavity cancers. In the last decades, despite 
progress in therapeutic strategies of OSCC, the 5-year survival 
rate showed no significant improvement, remaining slightly 
below 50%.
Nicotinamide N-Methyltransferase (NNMT) is a drug-
metabolizing enzyme that is overexpressed in several tumors, 
including OSCC. In particular, NNMT overexpression in 
OSCC inversely correlates with lymph node metastasis, pT, 
pathological staging and histological grading. In addition to 
the potential role of NNMT as a prognostic factor, the mea-
surement of salivary NNMT could serve as biomarker for ear-
ly diagnosis of OSCC. In this study, in order to further explore 
the biological function of NNMT in OSCC cell metabolism, 
we investigated the effects of plasmid-mediated overexpres-
sion of NNMT in OSCC cell line.
METHODS: Human oral cancer cell line HSC-2 was trans-
fected with the pcDNA3-NNMT plasmid. Control cells were 
transfected with the empty vector (pcDNA3) or treated with 
transfection reagent only (mock). Real-Time PCR, Western 
blot, and HPLC assay were used to evaluate NNMT expres-
sion, both at mRNA and protein levels. The assessment of cell 
proliferation was performed with MTT colorimetric assay. 
Furthermore, the effect of NNMT upregulation on β-catenin, 
survivin, and Ki-67 expression was also investigated. Data 
were analyzed using GraphPad Prism software. Differences 
between groups were determined using the Kruskal-Wallis 
test.
RESULTS: Compared with mock and pcDNA3-treated, cells 
transfected with pcDNA3-NNMT displayed significantly 
increased NNMT expression levels. Real-Time PCR showed a 
significant NNMT upregulation, that was confirmed at protein 
level by Western blot analysis. Furthermore, NNMT specific 
activity was significantly higher in transfected cells compared 
with controls. The results of MTT colorimetric assay showed 
that pcDNA3-NNMT plasmid was able to increase cell growth 
of HSC-2 cells compared with controls.
In order to explore the potential involvement of NNMT in 
cellular pathways, such as apoptosis, cell proliferation and cell 
signaling, we examined whether NNMT overexpression was 
able to affect the expression of β-catenin, survivin, and Ki-67.
The results seem to indicate a statistically significant upregu-
lation of survivin ǻEx3 isoform in pcDNA3-NNMT plasmid 
transfected cells, while the expression of 3B and 2α survivin 
isoforms was not detectable. 
CONCLUSION: Our results show that NNMT overexpression 
in OSCC cell line significantly increases cell growth. The 
effect on the antiapoptotic survivin ǻEx3 isoform seems to 
suggest a possible involvement of NNMT in the proliferation 
and tumorigenic capacity of OSCC cells.
Prognostic value of mithocondrial DNA analysis 
in patients with secondary oral squamous cell 
carcinoma
D. B. Gissi, L. Sozzi, L. Luccarini, C. Amadasi, S. Kavaja, 
D. Servidio, L. Alessi, A. Gabusi
Department of Biomedical and Neuromotor Sciences, Section of 
Oral Sciences, University of Bologna, Bologna
BACKGROUND: In head and neck oncology a novel clas-
sification of the secondary tumors was recently proposed 
on the basis of the clonal analysis of the tumors and the 
genetically altered mucosal field. Second neoplastic lesions 
can be classified as: Second Primary Tumors (SPTs) inde-
pendent from the index tumor at the molecular level, Local 
Recurrences (LRs) or metastases that are instead related 
to the primary tumor and ‘‘second field tumors” (SFTs), 
derived from the same genetically altered mucosal field 
as the primary tumor. The distinction between LR, SPT 
and SFT is not a simply problem of classification but may 
influence prognosis and the choice of treatment. mtDNA 
(D-loop) sequence analysis was proposed in previous stud-
ies as a reliable method for establishing the clonal relation-
ship between two neoplastic manifestations. In the present 
study mtDNA D-loop analysis was applied in a group of 
consecutive patients experiencing a second loco-regional 
neoplastic manifestation after surgical resection of a primary 
Oral Squamous Cell Carcinoma (OSCC). The purpose was 
to evaluate differences in terms of survival rate between 
LRs, SPTs and SFTs.
METHODS: The study population consisted of 24 patients 
who experienced a second neoplastic lesion after a surgical 
resection of a primary OSCC. 21/24 (87,5%) were limited 
to the oral cavity whereas 3/24 (12,5%) presented a neck 
nodal metastasis (LNM) as second event. mtDNA D-loop 
analysis was performed by deep sequencing and phylo-
genetic clusterization in all index OSCCs, in all second-
ary events and in respective normal mucosa. Disease-free 
survival endpoints was defined as the duration between 
appearance of second neoplastic lesion and dead of disease 
or last follow-up visit.
RESULTS: mtDNA analysis showed 7/24 second neoplas-
tic events (31,1%) phylogenetically related to index OSCC, 
and 17/24 cases (68,9%) phylogenetically independent. The 
genetic distinction of secondary tumours in LR, SPT and SFT 
was acquired on the basis of the phylogenetic relationship 
between normal mucosa of index OSCC and normal mucosa 
of secondary OSCC. All 7 clonal paired tumours showed 
respective normal mucosa phylogenetically related, suggest-
ing a genetic diagnosis of LR. Among non clonal patients 3 
out of 17 presented respective normal mucosa phylogeneti-
cally related, suggesting a genetic diagnosis of SPT whereas 
in remaining 14 out of 17 non clonal paired lesions also the 
respective normal mucosa resulted phylogenetically distant 
entities suggesting the presence of an altered mucosal field 
and a genetic diagnosis of SFT. The presence of an altered 
mucosal field in non clonal patients resulted a variable signifi-
cantly related with a better survival rate (p<.05), indeed 2/17 
(11,8%) SFTs events failed as compared to 5/7 LR. (71,4%) 
and 3/3 SPTs (100%). 
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